Researchers from the University of Sheffield have found vital new evidence on how to target and reverse the effects caused by one of the most common genetic causes of Parkinson’s. Continue reading
Just one shot of dopamine cells derived from stem cells could be enough to reverse many of the features of Parkinson’s disease for decades – and the barriers to developing such a treatment are finally being overcome.
Professor Roger Barker has a dream: by the time he retires in 15 years, he would like to seestem cell transplants for Parkinson’s disease available on the NHS.
BRIDGEWATER, Pa. (AP) — Parkinson’s robs people of the ability to control their movements, but some patients in Beaver County are seeing big results from a physical therapy program designed to counteract the symptoms of the degenerative disease.
While there is no cure for Parkinson’s disease and little is known about the cause, experts know that people with the nervous system disorder have trouble with slowness of movement, and their movements are also small, said Dale Reckless, facility director of M-R-S Physical Therapy in Bridgewater.
But the Lee Silverman Voice Treatment Big (LSVT Big) therapy program, which Reckless brought to M-R-S and Beaver County earlier this year, is aimed at keeping people’s movements big and quick in order to counteract those symptoms.
University of Adelaide neuroscience researchers are investigating markers for potential earlier diagnosis and treatment of Parkinson’s disease. The researchers are studying the molecular basis of non-motor symptoms of Parkinson’s disease, rather than the better-known clinical symptoms of impaired movement. These “non-motor” symptoms include cognitive impairment, depression and anxiety – and they can appear several years before the emergence of motor symptoms.
Timing is everything in business; especially where groundbreaking medical treatments, investments and acquisitions are concerned. So when a pioneering med-tech start-up comes up with a new treatment for Parkinson’s disease – effectively a next generation pacemaker for the brain – the business and investment world takes notice.
The World Parkinson Coalition (WPC) is hosting its first ever WPC Scientific Update online for free September 30 to October 1.
WPC Scientific Update: Parkinson Pipeline Umbrella will take place over three days in six one-hour sessions at 12 p.m. ET/9 a.m. PT and at 2 p.m. ET/ 11 p.m. PT. In addition to the live webcast, the sessions will archived for later viewing.
Sessions will be about the latest scientific updates from the Parkinson’s research world. Thefull program is available online. Participants are also encouraged to tweet before and during the sessions using the hashtag #WPCwebcast.
For more information and to register, click here.
Entia Biosciences Inc. (OTC: ERGO), an emerging leader in the field of nutrigenomics, was recently awarded a grant from the Michael J. Fox Foundation to conduct a preclinical study evaluating its ErgoD2® medical food as a potential therapy for the treatment of Parkinson’s Disease. Approximately 60,000 Americans are diagnosed with PD each year, with an estimated one million living with the disease.
To syndicate this article, or for more information, please contact us online or call (406) 862-5400.
CHAPEL HILL — Researchers at the UNC School of Medicine have discovered how neurons and cancer cells prevent cell death, which may bring new insight into both Parkinson’s disease and cancer treatment.
New TAU study confirms creative energy in Parkinson’s sufferers is greater than in healthy individuals
Prof. Rivka Inzelberg of Tel Aviv University’s Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson’s patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson’s disease and artistic inclination.
TORONTO, ONTARIO–(Marketwired – July 17, 2014) – Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, today announced that following communication from the United States Food and Drug Administration (“the FDA”) on July 16, 2014, Phase 2 clinical studies for APL-130277 will commence immediately.